Document is current

Article History

Accepted: 13 January 2025

First Online: 3 February 2025

Competing interests

: J.L. reports honoraria from Cancer GRACE, Community Cancer Education Inc., Physicians’ Education Resource, Targeted Oncology and VJ Oncology; advisory board participation for Amgen, Astellas and AstraZeneca; institutional research support from Erasca, Genentech, Kronos Bio, Novartis and Revolution Medicines; and personal fees from Blueprint Medicines, Daiichi Sankyo and Erasca. A patent filed by Memorial Sloan Kettering Cancer Center related to multimodal features to predict response to immunotherapy (PCT/US2023/115872) is pending. G.J.H. reports grants or contracts from ACCRF, Actuate Therapeutics, ASCO CCF, Bicara, Bristol Myers Squibb, Elevar Therapeutics, Exicure, Gateway for Cancer Research, Genentech, GSK, ImmunityBio, Kartos, Kite (a Gilead company), KSQ Therapeutics, Kura Oncology, Regeneron, Repertoire, Sanofi Genzyme, Secura Bio and V Foundation; and advisory roles for and/or honoraria from Bicara, Bio-Rad, Boxer Capital, Bristol Myers Squibb, Coherus, Elevar, Exicure, General Catalyst, Guardian Bio, KSQ Therapeutics, Kura Oncology, Massachusetts Medical Society, Merck, Naveris, Nextech, Prelude, Rain, Regeneron, Remix, Replimune, Sanofi Genzyme, SIRPant and Surface Oncology. S.G.D. reports honoraria from and/or advisory board participation for Amgen, Bayer, InhibRx and Jazz Pharmaceuticals; and travel expenses from LOXO Oncology, Roche and Salarius. G.I.S. reports personal fees from Artios, Bayer, Bicycle Therapeutics, Blueprint Medicines, Boehringer Ingelheim, Concarlo Holdings, Cybrexa Therapeutics, CytomX Therapeutics, ImmunoMet, Janssen, Kymera Therapeutics, Merck KGaA/EMD-Serono, Syros, Xinthera and Zentalis; grants from Bristol Myers Squibb, Eli Lilly, Merck KGaA/EMD-Serono, Pfizer and Tango; has a patent for “Dosage regimen for sapacitabine and seliciclib”, issued to Cyclacel Pharmaceuticals and G.I.S., and a patent for “Compositions and methods for predicting response and resistance to CDK4/6 inhibition”, issued to Liam Cornell and G.I.S. C.A.F. reports research funding and consultancy fees from Boehringer Ingelheim.